Pangaea Oncology, S.A (PANG) Fair Value & Analysis
Healthcare · ES · Market cap €56.7M
Fair value as of: Jun 24, 2026
Analysis
Pangaea Oncology, S.A (PANG) currently trades at €1.56, while our model-based Fair Value estimate is €2.67 — implying the stock looks roughly 71.2% undervalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. It offers molecular diagnostics, such as mutation analysis in tissue and liquid biopsy, gene amplification and translocation testing, immunohistochemistry and fluorescence in-situ hybridization, and gene expression profiling; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation. The company also provides biomarker discovery to improve treatment through identification of novel theranostic biomarkers. Pangaea Oncology, S.A. was incorporated in 2006 and is based in Barcelona, Spain.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Pangaea Oncology, S.A (PANG) undervalued?
What is the fair value of PANG?
What is the quality score of PANG?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.